Locations:
SearchAdvertisement
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings strengthen evidence for risk-reducing procedures
Findings from large database important to inform clinical practice
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant
Offers a new option for patients 60 and older with relapsed/refractory disease
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression
What’s coming up at ASH and beyond
Retrospective study evaluates clinical upstaging during neoadjuvant treatment
Advertisement
Advertisement